Nutra Pharma Corp under the ticker symbol NPHC. Here is some more information that we have about Nutra Pharma Corp

Get our alerts and future stock picks in your email inbox

Nutra Pharma Corp
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma Corporation, through its subsidiary, ReceptoPharm, engages in the development of Cobroxin, Nyloxin OTC, and Nyloxin Rx for the treatment of moderate to severe chronic pain; RPI-78M for the treatment of neurological diseases, including Multiple Sclerosis, Adrenomyeloneuropathy, Amyotrophic Lateral Sclerosis, and Myasthenia Gravis; and RPI-MN for the treatment of viral diseases comprising HIV/AIDS and herpes. ReceptoPharm also provides contract research services through its ISO class 5 and good manufacturing practice certified facilities to third-party biotechnology and pharmaceutical companies. In addition, the company, through its other subsidiary, Designer Diagnostics, involves in the research, development, and sale of diagnostic test kits used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria. Nutra Pharma Corporation continues to identify intellectual property and companies in the biotechnology arena. The company was founded in 2000 and is based in Coral Springs, Florida.
Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , announced today that they have received their first manufacturing run ...
  Read More...
Nutra Pharma Letter to Shareholders
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that the Company's ...
  Read More...
NUTRA PHARMA CORP Financials
  Read More...
10-Q for Nutra Pharma Corp.
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q, Quarterly Report
  Read More...
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing the recertification of their Plantation, Florida laboratory ...
  Read More...
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
[Marketwired] - Nutra Pharma Corp
  Read More...
Nutra Pharma Provides Nyloxin(R) Marketing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing updates to the marketing plan for their over-the-counter ...
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q/A, Quarterly Report
  Read More...
Nutra Pharma Announces Nyloxin Television Commercial Rollout
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a company that has the exclusive rights ...
  Read More...
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
Nutra Pharma Announces Contracts for Nyloxin Television Commercials
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have engaged ...
  Read More...
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have received ...
  Read More...
NUTRA PHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articles of
  Read More...
10-K for Nutra Pharma Corp.
  Read More...
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have engaged ...
  Read More...
NUTRA PHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  Read More...
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is providing an update regarding their plan to market their over-the-counter ...
  Read More...
NUTRA PHARMA CORP Files SEC form 10-K, Annual Report
  Read More...